James Son, MD
Rheumatology · Cranberry Township, PANPI 1730534199
Payments from drug & device makers
What this record shows
This record is dominated by grants: $74,236 of the $76,931 with a category attached, or 96.5%. Pfizer accounts for 96.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $37,118 and has fallen 99.8% since, to $62 in 2025. Among rheumatology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $646.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$74K
- AbbVie$669
- Amgen$440
- UCB, Inc.$303
- E.r. Squibb & Sons, L.L.C.$264
- Johnson & Johnson$225
- plus $637 from 11 others
What the payments were for
- Grants$74,23696%
- Food & beverage$2,6954%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $74,392 |
| AbbVie | 34 | $669 |
| Amgen | 17 | $440 |
| UCB, Inc. | 11 | $303 |
| E.r. Squibb & Sons, L.L.C. | 12 | $264 |
| Johnson & Johnson | 10 | $225 |
| Novartis | 6 | $180 |
| Aurinia Pharma U.S., Inc. | 4 | $111 |
| AstraZeneca | 3 | $65 |
| Organon | 3 | $59 |
| Fresenius Kabi USA, LLC | 2 | $57 |
| Radius Health, Inc. | 2 | $51 |
| Biocon Biologics Inc | 1 | $28 |
| Sandoz | 1 | $28 |
| Sobi, Inc | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
How this compares
$76,931 in reported general payments places this provider in the 90th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 35 | $249,452 |
| Enbrel SureclickEtanercept | 28 | $204,929 |
| Hydroxychloroquine Sulfate | 116 | $7,540 |
| MethotrexateMethotrexate Sodium | 156 | $6,520 |
| Mycophenolate Mofetil | 22 | $2,677 |
| Leflunomide | 29 | $2,275 |
| Celecoxib | 33 | $1,287 |
| Prednisone | 130 | $1,256 |
| Duloxetine Hcl | 36 | $1,045 |
| Gabapentin | 51 | $1,001 |
| Colchicine | 18 | $910 |
| Allopurinol | 64 | $616 |
| Alendronate Sodium | 18 | $348 |
| Tramadol Hcl | 14 | $134 |
| Meloxicam | 23 | $103 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Cranberry Township
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
- Alan KivitzDuncansville$936K
- Paula HerringNewtown Square$920K
- Rohit AggarwalPittsburgh$810K
- Frederick MurphyDuncansville$494K
- Peter MerkelRadnor$479K
- Martin BergmanRidley Park$458K
- Alexis Ogdie-BeattyPhiladelphia$433K
- Ellen FieldBethlehem$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.